ProQR Therapeutics N.V (NASDAQ:PRQR) has a beta value of 0.38 and has seen 19.03 million shares traded in the recent trading session. The company, currently valued at $256.48M, closed the recent trade at $3.14 per share which meant it gained $1.33 on the day or 73.48% during that session. The PRQR stock price is -4.78% off its 52-week high price of $3.29 and 64.65% above the 52-week low of $1.11. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.19 million shares traded. The 3-month trading volume is 129.38K shares.
The consensus among analysts is that ProQR Therapeutics N.V (PRQR) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
Sporting 73.48% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PRQR stock price touched $3.14 or saw a rise of 20.1%. Year-to-date, ProQR Therapeutics N.V shares have moved 58.59%, while the 5-day performance has seen it change 67.91%. Over the past 30 days, the shares of ProQR Therapeutics N.V (NASDAQ:PRQR) have changed 71.58%. Short interest in the company has seen 0.15 million shares shorted with days to cover at 1.39.
Wall Street analysts have a consensus price target for the stock at $3.75, which means that the shares’ value could jump 16.27% from the levels at last check today. The projected low price target is $2.0 while the price target rests at a high of $5.0. In that case, then, we find that the latest price level in today’s session is -59.24% off the targeted high while a plunge would see the stock lose 36.31% from the levels at last check today.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
Figures show that ProQR Therapeutics N.V shares have outperformed across the wider relevant industry. The company’s shares have gained 65.26% over the past 6 months, with this year growth rate of 18.42%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be 176.10%.
5 analysts offering their estimates for the company have set an average revenue estimate of 12.08M for the current quarter. 4 have an estimated revenue figure of 5.55M for the next ending quarter. Year-ago sales stood 1.49M and 6.75M respectively for this quarter and the next, and analysts expect sales will grow by 711.80% for the current quarter and 176.10% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 21.74% over the past 5 years.
PRQR Dividends
ProQR Therapeutics N.V is expected to release its next earnings report on 2024-Aug-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ProQR Therapeutics N.V (NASDAQ:PRQR)’s Major holders
The top two institutional holders are PRIVIUM FUND MANAGEMENT B.V. with over 5.58 million shares worth more than $9.21 million. As of 2024-06-30, PRIVIUM FUND MANAGEMENT B.V. held 6.8416% of shares outstanding.
The other major institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., with the holding of over 3.63 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.02 million and represent 4.4446% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Delaware Group Equity Fds IV-Delaware Healthcare Fund and Fidelity NASDAQ Composite Index Fund. As of Jun 30, 2024, the former fund manager holds about 0.76% shares in the company for having 620.0 shares of worth $2.05 million while later fund manager owns 46.67 shares of worth $0.15 million as of Aug 31, 2024, which makes it owner of about 0.06% of company’s outstanding stock.
